Patterson-UTI Energy Inc. Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Patterson-UTI Energy Inc. Common Stock trades at $11.45 (market cap $4.28B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 17.9× Patterson-UTI Energy Inc. Common Stock's market cap, and Patterson-UTI Energy Inc. Common Stock pays the higher dividend (3.56%). Which is the better fit depends on your goals — on Pluang, investors hold Patterson-UTI Energy Inc. Common Stock for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PTEN | REGN | |
|---|---|---|
Market Cap | $4.28B | $76.40B |
Volume | 5,046,340 | 626,381 |
Sector | Energy | Health |
52-Week High | $13.15 | $852.03 |
52-Week Low | $5.37 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $5.37B | $71.12B |
Dividend Yield | 3.56% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Patterson-UTI Energy provides drilling, completion, and other oilfield services for oil and gas producers in the United States.
Read more on PTEN →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →